Investing
Drugmaker Gilead to acquire CymaBay for $4.3 billion
© Reuters. FILE PHOTO: Gilead Sciences is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
(Reuters) – Gilead Sciences (NASDAQ:) on Monday said it will acquire CymaBay Therapeutics (NASDAQ:) for $4.3 billion, to expand its portfolio of liver disease drugs.
The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.
CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.
Shares of CymaBay were halted ahead of the announcement in premarket hours.
Read the full article here
-
Make Money4 days ago
How to Create and Sell Digital Products Online (Make Extra Money)
-
Investing4 days ago
Is Apple Releasing an ‘Ultra-Thin’ iPhone 17 Air? New Report
-
Side Hustles5 days ago
Create Your Wealthy, Purposeful Life: Business Expert’s Tips
-
Investing4 days ago
US data center electricity and water use to increase significantly by 2028: report By Investing.com
-
Investing3 days ago
Moldova breakaway region to face new power cuts on Saturday, officials say By Reuters
-
Investing3 days ago
Reebok Co-Founder Backs Syntilay’s New AI, 3D-Printed Shoe
-
Side Hustles3 days ago
How to Survive High-Demand Seasons Without Losing Customers
-
Side Hustles5 days ago
Minimum Wage Is Increasing In These 21 States This Year